Journal Article Summary
The article investigates the impact of various health policies on the accessibility of targeted anti-cancer medications in Nanjing, China, particularly focusing on drugs used for treating non-small cell lung cancer. This topic is significant due to the rising incidence of cancer and the associated financial burdens on patients and families, especially in a country where cancer treatment costs can be prohibitively high. The study aims to determine whether national pricing negotiations, the National Health Insurance Coverage (NHIC) policy, and a volume-based purchasing (VBP) pilot program have effectively improved access to three specific anti-cancer drugs: gefitinib, bevacizumab, and recombinant human endostatin.
To conduct the study, researchers analyzed hospital procurement data from January 2013 to December 2020 using an interrupted time series design. They found that after the implementation of the health policies, the utilization of the three drugs significantly increased, along with a notable decrease in their prices. Specifically, the daily cost of these medications dropped substantially, and their availability in hospitals improved, indicating that the policies had a positive effect on both access and affordability for patients.
However, the study has limitations, including its focus on a single city, which may not represent the broader situation across China. Additionally, the research did not include data from private hospitals or retail pharmacies, potentially affecting the overall accessibility of these drugs. Patients and caregivers should discuss these findings with healthcare professionals to understand how these policies may influence their treatment options and financial responsibilities, as well as to explore any available patient assistance programs that could help alleviate costs.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Liu Yanyan, Yi Huining, Fang Kexin, Bao Yuwen, Li Xin. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis. Frontiers in Public Health 2022. DOI: 10.3389/fpubh.2022.942638. PMID: 35937254. PMCID: PMC9353396.
Featured Pill Pals Product
Acetaminophen 500 MG Caplets ---1,000 Count --- Generic For Tylenol --- Major / Rugby --- Over The Counter
Acetaminophen 500 MG Caplets —1,000 Count — Generic For Tylenol — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
